TY  - JOUR
AU  - Allard, Pierre
AU  - Alhaj, Nareen
AU  - Lobitz, Stephan
AU  - Cario, Holger
AU  - Jarisch, Andreas
AU  - Grosse, Regine
AU  - Oevermann, Lena
AU  - Hakimeh, Dani
AU  - Tagliaferri, Laura
AU  - Kohne, Elisabeth
AU  - Kopp-Schneider, Annette
AU  - Kulozik, Andreas E
AU  - Kunz, Joachim B
TI  - Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea.
JO  - Haematologica
VL  - 107
IS  - 7
SN  - 1592-8721
CY  - Pavia
PB  - Ferrata Storti Found
M1  - DKFZ-2021-02377
SP  - 1577-1588
PY  - 2022
N1  - 2022 Jul 1;107(7):1577-1588
AB  - The course of sickle cell disease (SCD) is modified by polymorphisms boosting fetal hemoglobin (HbF) synthesis. However, it has remained an open question how these polymorphisms affect patients who are treated with the HbF-inducing drug hydroxyurea/hydroxycarbamide. The German SCD registry offers the opportunity to answer this question, because >90
LB  - PUB:(DE-HGF)16
C6  - pmid:34706496
DO  - DOI:10.3324/haematol.2021.278952
UR  - https://inrepo02.dkfz.de/record/177243
ER  -